Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation

• US 20070253913A1
• Filed: 03/13/2007
• Published: 11/01/2007
• Est. Priority Date: 09/10/2003
• Status: Abandoned Application

• Current Assignee: MAP Pharmaceuticals, Inc. (Abbvie Incorporated)
• Original Assignee: MAP Pharmaceuticals, Inc. (Abbvie Incorporated)
• Inventors: Mohsen, Nahed, Pavkov, Richard, Armer, Thomas
• Application Number:
  US11/717,276
• Publication Number:
  US 20070253913A1
• Time in Patent Office: Days
• US Class Current: 424/46
• CPC Class Codes: A61K 31/01 Hydrocarbons
• CPC Class Codes: A61K 9/0078 for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
• CPC Class Codes: A61K 9/008 comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
• CPC Class Codes: A61P 25/06 Antimigraine agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Pharmaceutical aerosol formulations of dihydroergotamine, or pharmaceutically acceptable salts thereof, to administer dry powders and propellant suspensions via pulmonary aerosol or nasal spray inhalation. Such formulations may be used for the treatment of various disease states and conditions, including, but not limited to, migraine headaches. The dihydroergotamine particles are produced using a supercritical fluid process. The aerosol formulations disclosed have superior stability, purity and comprise particle of respirable size particularly suitable for pulmonary delivery.

Claims

1. A surfactant and excipient free pharmaceutical aerosol formulation for delivery by inhalation, said aerosol formulation consisting essentially of:

(i) a particulate powdered medicament produced by a supercritical fluid process, said particulate powdered medicament having a mass mean aerodynamic diameter of 5 microns or less and being dihydroergotamine; and

(ii) at least one hydrofluoralkane propellant, such that the formulation has a respirable fraction of 40% or greater.

2. The aerosol formulation of claim 1 where the dihydroergotamine is the mesylate salt.

3. The aerosol formulation of claim 1 where said supercritical fluid process is selected from the group consisting of:

rapid expansion, solution enhanced diffusion, gas-anti solvent, supercritical antisolvent, precipitation from gas-saturated solution, precipitation with compressed antisolvent and aerosol solvent extraction system.

4. The aerosol formulation of claim 1 where said hydrofluoroalkane propellant is a mixture of 30% by weight 1,1,1,2-tetrafluoroethane and 70% by weight 1,1,1,2,3,3,3-heptafuoro-n-propane or 70% by weight 1,1,1,2-tetrafluoroethane and 30% by weight 1,1,1,2,3,3,3-heptafuoro-n-propane.

5. The aerosol formulation of claim 1 where said hydrofluoralkane propellant is 100% 1,1,1,2-tetrafluoroethane or 100% 1,1,1,2,3,3,3-heptafuoro-n-propane.

6. The aerosol formulation of claim 1 where said hydrofluoralkane propellant is selected from the group consisting of:

1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafuoro-n-propane and a mixture of 1,1,1,2-tetrafluoroethane and 1,1,1,2,3,3,3-heptafuoro-n-propane.

7. The aerosol formulation of claim 1 where the powdered particulate medicament has a respirable fraction of 45% or more.

8. The aerosol formulation of claim 1 where the particulate powdered medicament having a mass mean aerodynamic diameter of 5 microns or less

9. The aerosol formulation of claim 1 administered by a metered dose inhaler.

11. The aerosol formulation of claim 1 where the dihydroergotamine is the mesylate salt.

12. The aerosol formulation of claim 1 where said supercritical fluid process is selected from the group consisting of:

rapid expansion, solution enhanced diffusion, gas-anti solvent, supercritical antisolvent, precipitation from gas-saturated solution, precipitation with compressed antisolvent and aerosol solvent extraction system.

13. The aerosol formulation of claim 1 where said hydrofluoroalkane propellant is a mixture of 30% by weight 1,1,1,2-tetrafluoroethane and 70% by weight 1,1,1,2,3,3,3-heptafuoro-n-propane or 70% by weight 1,1,1,2-tetrafluoroethane and 30% by weight 1,1,1,2,3,3,3-heptafuoro-n-propane.

14. The aerosol formulation of claim 1 where said hydrofluoralkane propellant is 100% 1,1,1,2-tetrafluoroethane or 100% 1,1,1,2,3,3,3-heptafuoro-n-propane.

15. The aerosol formulation of claim 1 where said hydrofluoralkane propellant is selected from the group consisting of:

1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafuoro-n-propane and a mixture of 1,1,1,2-tetrafluoroethane and 1,1,1,2,3,3,3-heptafuoro-n-propane.

16. The aerosol formulation of claim 1 where the powdered particulate medicament has a respirable fraction of 45% or more.

17. The aerosol formulation of claim 1 where the particulate powdered medicament having a mass mean aerodynamic diameter of 5 microns or less

18. The aerosol formulation of claim 1 administered by a metered dose inhaler.

10. A pharmaceutical aerosol formulation for delivery by inhalation, said aerosol formulation consisting essentially of:

(i) a particulate powdered medicament produced by a supercritical fluid process, said particulate powdered medicament having a mass mean aerodynamic diameter of 5 microns or less and being dihydroergotamine; and

(iii) a surfactant, said surfactant being oleate, a stearate, a myristate, an alkylether, an alklyarylether, a sorbate or mixtures of any of the foregoing, and said surfactant being present in a mass ratio to the dihydroergotamine of greater than 0.004 to 1, but less than 0.05 to 1 such that the formulation has a respirable fraction of 40% or greater.